Delivery Order SPE2DB22D3016-SPE2DB24FAEC0
- Not listed
- This federal contract award, valued at $1,982.86, was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a subsidiary of Cencora, Inc. The contract is for the delivery of 4564415866 - Ropivacaine 0.2% 400 mg/200 ml 200 ml, a medical product, to support military healthcare programs. The contract has an ultimate completion date of April 29, 2024 and is a Firm Fixed Price Delivery Order. The contract was awarded on April 26, 2024 and is not designated as a set-aside....
- This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a subsidiary of Cencora, Inc. The $3,174.42 firm fixed-price delivery order is for the supply of Ropivacaine 0.2% 400 mg/200 ml medication, with a completion date of January 29, 2024. Amerisourcebergen Drug Corp holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at up to $999,999,999.00 through November 2026. This IDC serves as the primary...
- This federal contract award was made by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $3,324.51, is for the delivery of 400 mg/200 ml of the medication Ropivacaine 0.2% in 200 ml vials. The contract has an ultimate completion date of January 30, 2025 and is a Firm Fixed Price Delivery Order. This contract is not associated with any set-aside designation. Amerisourcebergen Drug...
- This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distribution company. The $1,883.24 firm-fixed-price delivery order is for the supply of 4565878585 - Ropivacaine 0.2% 400 mg/200 ml medication. The contract has a period of performance through September 20, 2024 and does not have a set-aside designation. Amerisourcebergen Drug Corp's Corporate Office division is the prime contractor for this award. This delivery...
- This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor, to provide Ropivacaine 0.2% 400 mg/200 ml injections. The contract, valued at $9,396.54, is a firm fixed-price delivery order with an ultimate completion date of October 17, 2023. Amerisourcebergen Drug Corp is a subsidiary of the parent company Cencora, Inc., which does business as Amerisourcebergen. The company holds a significant Indefinite...
- This federal contract award, identified as SPE2DB20D1109|SPE2DB25FN95V, was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of Ropivacaine 0.2% 400 mg/200 ml, a pharmaceutical product, with a ceiling value of $3,605.54 and a performance period through April 28, 2025. The contract is a Firm Fixed Price Delivery Order, without any set-aside designation, indicating...
- This is a federal contract award from the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $1,935.46, is for the delivery of 4567631013 - Ropivacaine 0.2% 400 mg/200 ml in 200 ml containers. The contract is a Delivery Order with a Firm Fixed Price pricing type and has an ultimate completion date of March 20, 2025. This award is part of a larger Indefinite Delivery Contract (IDC) that...
- This is a federal contract award to Amerisourcebergen Drug Corp, a subsidiary of Cencora, Inc., by the Defense Logistics Agency (DLA) Medical Supply Chain for the delivery of Ropivacaine 0.2% 400 mg/200 ml injectables. The contract, identified as SPE2DX15D1053|SPE2DX24F6CZS, is a Firm Fixed Price Delivery Order with a ceiling value of $5,396.69 and a period of performance through November 27, 2023. The contract is not designated as a set-aside. Amerisourcebergen, a major pharmaceutical...
- This is a federal contract award from the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $3,639.35, is for the delivery of Ropivacaine 0.2% 400 mg/200 ml medication. The contract is a Firm Fixed Price Delivery Order with a completion date of February 24, 2025. This award is part of a larger Indefinite Delivery Contract (IDC) between AmerisourceBergen and the DLA Troop Support Medical,...
- This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a subsidiary of the parent company Cencora, Inc. The contract, valued at $5,002.00, is a delivery order for the supply of 400 mg/200 mL of Ropivacaine 0.2% solution. The award has a ceiling value of $5,002.00 and a completion date of February 13, 2024. The contract is a firm-fixed-price type with no set-aside designation, indicating open competition. Amerisourcebergen Drug Corp is a major...
- SPE2DB22D3016Indefinite Delivery Contract
- SPE2DB22D3016-SPE2DB24FAEC0Delivery Order
This federal contract award, identified as SPE2DB22D3016|SPE2DB24FAEC0, was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a subsidiary of Cencora, Inc. The contract, valued at $2,594.70, is for the delivery of Ropivacaine 0.2% 400 mg/200 mL medication. This is a Firm Fixed Price delivery order contract with an ultimate completion date of November 27, 2023. The contract does not have a set-aside designation, indicating it was awarded through full and open competition. Amerisourcebergen Drug Corp is a major pharmaceutical distributor that holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at up to $999,999,999.00 through November 2026. This IDC serves as the primary vehicle for the company to deliver a comprehensive range of pharmaceutical products and medical supplies to support military healthcare programs globally.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $2.6k | 11/24/23 |